MRI Radiomics Approach to Predict the Intracranial Efficacy of the Third Generation EGFR-TKI Osimertinib in NSCLC Patients with Brain Metastases

被引：0
|
作者：
Tang, X. [1 ]
Li, Y. [1 ]
Qian, W. -L. [1 ]
Han, P. -L. [1 ]
Yan, W. -F. [1 ]
Yang, Z. -G. [1 ]
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
MRI radiomics; osimertinib; intracranial efficacy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-38
引用
收藏
页码：S349 / S349
页数：1
相关论文
共 50 条
  • [1] Usage of EGFR-TKI and WBRT in NSCLC patients with brain metastases
    Chen, Yuh-Min
    ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 108 - 110
  • [2] The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
    Lu, S.
    Wang, Q.
    Zhang, G.
    Dong, X.
    Yang, C.
    Song, Y.
    Chang, G.
    Lu, Y.
    Pan, H.
    Chiu, C.
    Wang, Z.
    Feng, J.
    Zhou, J.
    Xu, X.
    Guo, R.
    Chen, J.
    Yang, H.
    Chen, Y.
    Yu, Z.
    Shiah, H.
    Wang, C.
    Yang, N.
    Fang, J.
    Wang, P.
    Wang, K.
    Hu, Y.
    He, J.
    Wang, Z.
    Shi, J.
    Chen, S.
    Cheng, Y.
    Su, W.
    Hsia, T.
    Cui, J.
    Sun, Y.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S209
  • [3] Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC
    Ying Fan
    Xinti Wang
    Yue Dong
    Enuo Cui
    Huan Wang
    Xinyan Sun
    Juan Su
    Yahong Luo
    Tao Yu
    Xiran Jiang
    European Radiology, 2023, 33 : 7902 - 7912
  • [4] Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC
    Fan, Ying
    Wang, Xinti
    Dong, Yue
    Cui, Enuo
    Wang, Huan
    Sun, Xinyan
    Su, Juan
    Luo, Yahong
    Yu, Tao
    Jiang, Xiran
    EUROPEAN RADIOLOGY, 2023, 33 (11) : 7902 - 7912
  • [5] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [6] Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases
    Qi, Haoran
    Hou, Yichen
    Zheng, Zhonghang
    Zheng, Mei
    Qiao, Qiang
    Wang, Zihao
    Sun, Xiaorong
    Xing, Ligang
    BMC CANCER, 2024, 24 (01)
  • [7] Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases
    Haoran Qi
    Yichen Hou
    Zhonghang Zheng
    Mei Zheng
    Qiang Qiao
    Zihao Wang
    Xiaorong Sun
    Ligang Xing
    BMC Cancer, 24
  • [8] The Feasibility of Osimertinib Treatment on Brain Metastases in NSCLC Patients After 1st Generation EGFR-TKI Resistance: A Preliminary Study
    Zhu, L.
    Zhang, S.
    Xia, B.
    Chen, X.
    Ma, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1910 - S1910
  • [9] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
  • [10] EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis
    Xia, X.
    Guo, M.
    He, J.
    Liang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S382 - S382
12345